Acurastem wins $7.5M to advance ALS treatment to clinical trials
Original source
Acurastem wins $7.5M to advance ALS treatment to clinical trials (opens in a new tab)Compass holds only the headline and link for this source, so the summary below is necessarily brief. Please read the original.
Acurastem has reportedly received $7.5 million to advance an amyotrophic lateral sclerosis (ALS) treatment toward clinical trials. The available source does not provide further details about the treatment or development plans.
Why this matters
The funding could support Acurastem’s efforts to move its ALS treatment toward testing in people. It does not show that the treatment is safe, effective or available, and no change to patient treatment is established.
Limitations and context
This report is based only on the headline and metadata of one news article. No primary research, trial information, funding terms or evidence of treatment benefit was available.